MLICM
TPTX

Metropolitan Life Insurance Company (MetLife)’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,761
Closed -$208K – 2390
2022
Q2 		$208K Sell
2,761
-224
-8% -$9.96K 0.01% 680
2022
Q1 		$80.1K Sell
2,985
-9,050
-75% -$304K ﹤0.01% 1344
2021
Q4 		$574K Hold
12,035
– – 0.01% 1328
2021
Q3 		$799K Sell
12,035
-589
-5% -$42K 0.01% 1128
2021
Q2 		$985K Buy
12,624
+2,521
+25% +$186K 0.01% 1019
2021
Q1 		$956K Sell
10,103
-376
-4% -$44.7K 0.01% 959
2020
Q4 		$1.28M Buy
10,479
+591
+6% +$64.7K 0.02% 729
2020
Q3 		$864K Buy
9,888
+1,213
+14% +$84.5K 0.01% 829
2020
Q2 		$560K Sell
8,675
-227
-3% -$13.1K 0.01% 1120
2020
Q1 		$398K Buy
8,902
+239
+3% +$12.7K 0.01% 1186
2019
Q4 		$540K Buy
8,663
+5,482
+172% +$261K 0.01% 1276
2019
Q3 		$120K Buy
3,181
+2,487
+358% +$108K ﹤0.01% 2203
2019
Q2 		$28.2K Buy
+694
New +$24.8K ﹤0.01% 2558

Metropolitan Life Insurance Company (MetLife)'s TPTX Position: Q3 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 2,761 shares — an estimated $208K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $1.28M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,761 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $208K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Turning Point Therapeutics, Inc. Common Stock position peaked at $1.28M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2022, filed 14 Nov 2022.